| P2093 | author name string | Paul L McCormack | |
| | Juliane Weber | |
| P2860 | cites work | Mechanism of Action of Atypical Antipsychotic Drugs and the Neurobiology of Schizophrenia | Q22241430 |
| | Asenapine: a novel psychopharmacologic agent with a unique human receptor signature | Q28270767 |
| | Effectiveness of antipsychotic drugs in patients with chronic schizophrenia | Q28273164 |
| | Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability | Q34869256 |
| | Bipolar disorder and health-related quality of life : review of burden of disease and clinical trials | Q36165238 |
| | The burden of schizophrenia on caregivers: a review | Q37058450 |
| | Central 5-HT2A and D2 dopamine receptor occupancy after sublingual administration of ORG 5222 in healthy men. | Q40892453 |
| | Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. | Q45934510 |
| | Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms | Q46130784 |
| | Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain | Q46141860 |
| | Electrophysiological characterization of the effects of asenapine at 5-HT(1A), 5-HT(2A), alpha(2)-adrenergic and D(2) receptors in the rat brain | Q46179248 |
| | Asenapine induces differential regional effects on serotonin receptor subtypes | Q46417433 |
| | Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus | Q46640346 |
| | The choice of antipsychotic drugs for schizophrenia | Q46711352 |
| | Differential regional and dose-related effects of asenapine on dopamine receptor subtypes | Q46735759 |
| | Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. | Q46947142 |
| | Asenapine in the treatment of negative symptoms of schizophrenia: clinical trial design and rationale | Q80359252 |
| P433 | issue | 9 | |
| P304 | page(s) | 781-792 | |
| P577 | publication date | 2009-09-01 | |
| P1433 | published in | CNS Drugs | Q5013183 |
| P1476 | title | Asenapine. | |
| P478 | volume | 23 | |